Track RNA and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Atrium Therapeutics, Inc. Common Stock
10578 Science Center Drive, San Diego, CA, United States, 92121
IPO
2013
Employees
511
Industry
Biotechnology
Sector
Healthcare
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 202613-13
0
Q4 20253-3
0
Q3 20254-4
0
3-quarter cumulative
20 sells0 buys
Analyst Ratings
6 analysts covering
Buy100%recommend buy
Buy
6
Hold
0
Sell
0